Install
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES VIEW ALL FEATURED COMPANIES V
- 5,218articles · 365d
- 1+ day agolatest article
- Sep 14, 2025earliest in window
- 87%with images
- 303avg words
- Medical 2,725
- Health & Wellness 2,685
- Economy, Business & Finance 2,580
- Finance & Business 1,825
- Business & Industrial 1,701
- Health 1,619
- Science & Technology 817
- News 672
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
4+ day, 10+ hour ago (980+ words) Patients with head and neck cancer who took Inhibrx Biosciences’ OX40 receptor agonist in combination with Merck’s Keytruda responded at a higher rate than those who took Keytruda alone in a Phase 2 trial, clearing the way for the biotech to access…...
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
4+ day, 11+ hour ago (346+ words) Structure Therapeutics is working to stake its claim in the obesity space Tuesday, reporting positive data from its two lead assets, an oral GLP-1 and a dual amylin and calcitonin receptor agonist. “Summer vacation may be coming to an end,…...
Maxwell Biosciences' Spinout SHU.ai Announces Closing of $1M Financing Round
3+ week, 2+ day ago (21+ words) Maxwell Biosciences’ Spinout SHU.ai Announces Closing of $1M Financing Round BioSpace Maxwell Biosciences’ Spinout SHU.ai Announces Closing of $1M Financing Round...
Out of sight, out of work? What’s driving remote job cuts
3+ week, 2+ day ago (662+ words) For some biotech and pharma employees, job security depends on whether their employers decide their positions are best done at the office. Staff at EMD Serono and Exelixis have seen that firsthand. Last month, 70 research and development (R&D) employees at…...
11 companies hiring in New Jersey
3+ week, 3+ day ago (171+ words) BioSpace Looking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data Here are 11 companies with open roles Situated within the Pharm Country hotbed, New Jersey offers more job…...
Ingenia Therapeutics Goes Public on KOSDAQ to Accelerate Pipeline of Next-Generation Vascular Antibody Therapeutics
3+ week, 4+ day ago (449+ words) BioSpace Ingenia Therapeutics Goes Public on KOSDAQ to Accelerate Pipeline of Next-Generation Vascular Antibody Therapeutics WATERTOWN, Mass.--(BUSINESS WIRE)--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced today that its shares have begun trading on the KOSDAQ…...
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
3+ week, 4+ day ago (580+ words) BioSpace bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly expands bioAffinity's commercial reach through AvMEDICAL's…...
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
3+ week, 4+ day ago (683+ words) BioSpace Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia - LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p…...
Aptitude Medical Systems, Inc. Appoints Co-Founder JP Wang as Co-CEO
3+ week, 5+ day ago (152+ words) Shared leadership structure formalizes how the founders already lead the company as the Aptitude enters its next stage of growth GOLETA, Calif., Aug. 17, 2026 /PRNewswire/ -- Aptitude Medical Systems, Inc. today announced that co-founder JP Wang has been appointed Co-Chief Executive Officer....
Olympus Announces Global Distribution Agreement with Endocision for Respiratory Cryobiopsy System
4+ week, 1+ day ago (219+ words) Portable Device is Designed to Support a Variety of Clinical Needs Under the agreement, Olympus will serve as the exclusive global distributor of the Endocision platform designed to support a variety of diagnostic and therapeutic bronchoscopic procedures. Olympus and Endocision…...